RAS Mutations Enhance Chemotherapy in AML

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD

July 22nd 2024

FDA Accepts Resubmitted BLA for Remestemcel-L in Pediatric SR-aGVHD

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

The agency has set a Prescription Drug User Fee Act date of January 7, 2025, for its decision on approving remestemcel-L in this patient population.

Russ Conroy

Overcoming Physical and Social Barriers in the Lymphoma Field

The agency has set a Prescription Drug User Fee Act date of January 7, 2025, for its decision on approving remestemcel-L in this patient population.

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Julie M. Vose, MD, MBA;Avyakta Kallam, MD

July 15th 2024

Telomere-Targeting Agent Demonstrates Tolerability in Advanced NSCLC

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

As of data cutoff, 6 patients with NSCLC in the phase 2 THIO-101 trial are receiving ongoing treatment with THIO plus cemiplimab after 12 months.

Nintedanib Does Not Significantly Improve PFS in Thyroid Cancer

As of data cutoff, 6 patients with NSCLC in the phase 2 THIO-101 trial are receiving ongoing treatment with THIO plus cemiplimab after 12 months.

An observed extension in progression-free survival with nintedanib vs placebo did not warrant continued development of the therapy for thyroid cancer.

Gabrielle Rocque;Joanne L. Blum, MD, PhD;Yan Ji;Eric Gauthier;Yao Wang;Monica Z. Montelongo;Joseph C. Cappelleri;Connie Chen;Meghan S. Karuturi;Debu Tripathy, MD

An observed extension in progression-free survival with nintedanib vs placebo did not warrant continued development of the therapy for thyroid cancer.

Related Content

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD

July 22nd 2024

FDA Accepts Resubmitted BLA for Remestemcel-L in Pediatric SR-aGVHD

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Russ Conroy

Overcoming Physical and Social Barriers in the Lymphoma Field

The agency has set a Prescription Drug User Fee Act date of January 7, 2025, for its decision on approving remestemcel-L in this patient population.

Julie M. Vose, MD, MBA;Avyakta Kallam, MD

July 15th 2024

Telomere-Targeting Agent Demonstrates Tolerability in Advanced NSCLC

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Nintedanib Does Not Significantly Improve PFS in Thyroid Cancer

As of data cutoff, 6 patients with NSCLC in the phase 2 THIO-101 trial are receiving ongoing treatment with THIO plus cemiplimab after 12 months.